BofA/Merrill Lynch Downgrades Karyopharm Therapeutics (KPTI) to Underperform

February 27, 2019 6:13 AM EST
Get Alerts KPTI Hot Sheet
Price: $5.45 +4.41%

Rating Summary:
    11 Buy, 3 Hold, 2 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 10 | Down: 8 | New: 36
Trade Now! 
Join SI Premium – FREE

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here.

BofA/Merrill Lynch analyst Ying Huang downgraded Karyopharm Therapeutics (NASDAQ: KPTI) from Neutral to Underperform with a price target of $5.00 (from $15.00).

For an analyst ratings summary and ratings history on Karyopharm Therapeutics click here. For more ratings news on Karyopharm Therapeutics click here.

Shares of Karyopharm Therapeutics closed at $4.20 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst PT Change, Downgrades

Related Entities

BofA/Merrill Lynch